Jeffery Smisek

MolecularMatch, Inc. is a Houston, Texas-based clinical informatics SaaS company founded in 2014 out of MD Anderson Cancer Center. The company was founded on the vision of using tumor molecular profiling, and outcomes from previously-treated patients, to provide the best personalized treatment for current patients. MolecularMatch delivers personalized, evidence-based therapeutic guidance and clinical trials matched to each patient. Customers include genetic labs, health information systems, biopharma, hospitals, and cancer centers.

Providing simple solutions to complex problems. Founded in 2019 by a world class team Lantha Sensors offers an alternative to costly and slow trace chemical analysis such as NMR and Karl Fischer titrations. We offer a range of portable, durable, and inexpensive chemical sensors that give simple, accurate results in minutes without the need for specialist staff or training. The company capitalizes on breakthrough discoveries in the field of Metal Organic Frameworks (MOFs) out of the University of Texas at Austin College of Natural Sciences.

Finch Therapeutics has a portfolio of microbiome assets including CP101, a late-stage, investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI). Additionally, Finch has pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Finch has a robust intellectual property estate reflecting the Company’s pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. In January 2023, Finch announced a decision to discontinue its Phase 3 trial of CP101 in recurrent CDI and focus on realizing the value of its intellectual property estate and other assets.

The Tahirih Justice Center is a national, non-profit organization that supports immigrant survivors seeking safety and justice. Our holistic, interdisciplinary model for service combines free legal and social services with bridge-building policy advocacy, and research-based training and education. We amplify the voices of survivors in communities, courts, and Congress to create a world where everyone can live in safety and with dignity.

MolecularMatch, Inc. is a Houston, Texas-based clinical informatics SaaS company founded in 2014 out of MD Anderson Cancer Center. The company was founded on the vision of using tumor molecular profiling, and outcomes from previously-treated patients, to provide the best personalized treatment for current patients. MolecularMatch delivers personalized, evidence-based therapeutic guidance and clinical trials matched to each patient. Customers include genetic labs, health information systems, biopharma, hospitals, and cancer centers.

Providing simple solutions to complex problems. Founded in 2019 by a world class team Lantha Sensors offers an alternative to costly and slow trace chemical analysis such as NMR and Karl Fischer titrations. We offer a range of portable, durable, and inexpensive chemical sensors that give simple, accurate results in minutes without the need for specialist staff or training. The company capitalizes on breakthrough discoveries in the field of Metal Organic Frameworks (MOFs) out of the University of Texas at Austin College of Natural Sciences.

Finch Therapeutics has a portfolio of microbiome assets including CP101, a late-stage, investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI). Additionally, Finch has pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Finch has a robust intellectual property estate reflecting the Company’s pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. In January 2023, Finch announced a decision to discontinue its Phase 3 trial of CP101 in recurrent CDI and focus on realizing the value of its intellectual property estate and other assets.